Tampa, FL (Feb. 9, 2005) - Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia. Given in pill form, Revlimid simultaneously blocks the growth of new blood vessels that nourish tumors (anti-angiogenesis) and stimulates the immune system to fight cancer cells. The study is reported in the Feb.10 issue of the New England Journal of Medicine.
Nearly 90 percent of MDS patients are anemic and require regular transfusions of red cells. In this study, 91 percent of the MDS patients with a chromosome abnormality named 5q minus syndrome became transfusion independent. The defective 5q chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer.
In another finding of the same study, all the patients with the 5q deletion who became transfusion independent also went into cytogenetic remission, meaning that the chromosome abnormality disappeared.
List, a professor of interdisciplinary oncology at the University of South Florida, initially developed the phase I clinical trial of Revlimid for treatment of MDS following his laboratory observations that the agent improved the growth of red blood cell precursors from MDS bone marrow. Celgene will submit the seminal findings of List's phase I trial - along with data from two recent confirmatory phase II clinical trials performed nationwide involving more than 350 patients with red blood cell transfusion-dependent MDS - to the U.S. Food and Drug Administration in a new drug application (NDA) for Revlimid as an innovative approach to treat the anemia of MDS patients with the 5q minus deletion.
In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in r
'"/>
Contact: Andrea Brunais
MediaRelations@moffitt.usf.edu
813-632-1478
University of South Florida Health
9-Feb-2005
Page: 1 2 Related medicine news :1.
Leukemia patients survive with stem cell transplant2.
Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight Leukemia3.
Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients4.
Promising New Drug Uses Antibody Targeted Chemotherapy To Fight Leukemia5.
University of Kentucky Markey Cancer Center Researchers Awarded Grant To Fight Leukemia Recurrence6.
OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia7.
Fertilization Protein Structure To AID in Leukemia Treatment8.
International gathering of experts to share retinoblastoma breakthroughs9.
Consumers to benefit from organic potato breakthrough10.
Biotech breakthrough in islet cell replacement for type 1 diabetes11.
4 out of 5 eligible patients missing opportunity to benefit from latest HIV breakthrough